Table 2.

Correlation between ISG15 expression and clinicopathological parameters

Variables	n	ISG15 mRNA		P	ISG15 protein		P
		High	Low		High	Low
Men	170	109	61	0.603	106	64	0.502
Women	20	14	6		14	6
Age (y)*
> 50	133	90	43	0.747	89	44	0.647
≤ 50	57	33	14		31	16
Hepatitis status
Active	130	85	45	0.783	85	45	0.349
Non-active	60	38	22		35	25
Liver cirrhosis
No	154	89	55	0.135	88	56	0.301
Yes	36	34	12		32	14
Tumor capsule
Presence	106	74	32	0.101	72	34	0.126
Absence	84	49	35		48	36
Tumor size
≤ 5 cm	86	52	34	0.262	52	34	0.484
> 5 cm	104	71	33		68	36
Tumor nodules
1	106	62	44	0.043	59	47	0.016
≥ 2	84	61	23		61	23
Recurrence
Yes	75	52	23	0.284	51	24	0.264
No	115	71	44		69	46
Microvascular invasion
No	57	32	25	0.104	32	25	0.189
Yes	133	91	42		88	45
Tumor differentiation
I-II	102	60	42	0.066	59	43	0.102
III-IV	88	63	25		61	27
Serum AFP
> 400 ng/mL	130	92	38	0.010	90	40	0.011
≤ 400 ng/mL	60	31	29		30	30
TNM stage
I	38	20	18	0.001	19	17	0.020
II	76	41	35		43	33
III	76	61	15		56	20

^*year-old.